0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Actavia Life Sciences
Its shares trade under the ticker RASP. It has been listed since 28 March 2014. In the fiscal year to 30 September 2014, it reported revenue of −$350 and a net loss of $40,035. At that date it held total assets of $6,685 and shareholders' equity of $5,705.
Rasna Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of therapeutics for the treatment of leukemia and lymphoma diseases. The company is headquartered in New York City, New York. The company went IPO on 2014-03-28. The firm is focused on the development of disease-modifying drugs candidates for leukemia and lymphoma. The firm is targeting nucleophosmin (NPM1)-mutated acute myeloid leukemi (AML) through direct and indirect disease-modifying approaches. AML includes acute and chronic. The company is also exploring inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, as approach against AML. The Company’s product candidate includes RASP-101, RASP-201 and RASP-301. RASP-101 is an anticancer therapeutic for treating NPM1 mutated acute myeloid leukemia (AML). Formulation of RASP-101 is being developed to conduct multi-center clinical trials in NPM1 mutated AML patients.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Mar 2014
- Website
- rasna.com ↗
Leadership
Pay as last reported
- Mr. Willy SimonIndependent Chairman of the Board
- Ms. Keeren ShahChief Financial Officer
- Mr. John BrancaccioIndependent Director$25,000
- Mr. Gary JacobIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rasna Therapeutics Inc. has a strong portfolio of innovative drugs in various stages of development. This provides them with a competitive advantage in the pharmaceutical industry.
- The company has a team of highly skilled and experienced researchers and scientists who are dedicated to driving innovation and discovering breakthrough therapies.
- Rasna Therapeutics Inc. has established strong partnerships with leading academic institutions and research organizations, allowing them access to cutting-edge technologies and resources.
Weaknesses
- The company currently relies heavily on external funding sources to support its research and development activities. This dependency on funding may limit their ability to progress with certain projects.
- Rasna Therapeutics Inc. has limited market presence and brand recognition compared to larger pharmaceutical companies. This may pose challenges in gaining market acceptance for their products.
- The company is vulnerable to regulatory changes and compliance requirements, which may result in delays or additional costs for their drug development process.
Opportunities
- The growing demand for innovative and effective therapies in the healthcare industry presents significant opportunities for Rasna Therapeutics Inc. to capitalize on their drug pipeline.
- Advancements in technology and research methodologies offer the company the opportunity to accelerate their drug discovery and development processes, potentially reducing time to market.
- Strategic collaborations and partnerships with established pharmaceutical companies can provide Rasna Therapeutics Inc. with access to additional resources, expertise, and market reach.
Threats
- The pharmaceutical industry is highly competitive, with numerous players vying for market share. Increased competition from both established companies and emerging biotech firms poses a threat to Rasna Therapeutics Inc.
- Changes in healthcare policies, pricing regulations, and reimbursement systems may impact the profitability and market access of the company's products.
- The risk of clinical trial failures, regulatory setbacks, and intellectual property infringements pose significant threats to the success and profitability of Rasna Therapeutics Inc.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.